In 2L cervical cancer, the company saw a confirmed ORR of 34.4% (n=70), In the highest dose used in 2L oropharyngeal squamous cell carcinoma, a subset of head and neck patients whose cancers are primarily driven by HPV, Corbus saw a confirmed ORR of 42.9% (n=21). CEO Yuval Cohen walks us through his analysis of the data.

Yuval Cohen describes why he believe his company's nectin-4 ADC has a next generation design, he covers the idea of integrin inhibition...